FDA Approves IV Maintenance Dosing Of Leqembi® (Lecanemab-Irmb) For The Treatment Of Early ...
Lecanemab is the result of a strategic research alliance between BioArctic and Eisai. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...